Xiaolin Zhang, Dizal CEO
September 6, 2022 10:17 AM EDT
R&D
China

#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

Kyle LaHucik

Senior Reporter

As­traZeneca spin­out Dizal said its can­cer drug cleared the pri­ma­ry goal in a Phase II tri­al of pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions, for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times